Matchmaking And Integration In The New World Of Diagnostics M&A

Nontraditional buyers, including Big Pharmas, life science tool companies, diversified conglomerates, and even food companies, are snapping up molecular diagnostics assets with increasing frequency, applying a variety of models to enhance their businesses.

More from Deal-Making

More from In Vivo